Activation of endogenous human stem cell-associated retroviruses (SCARs) and therapy-resistant phenotypes of malignant tumors

Please follow one of these links to view the audio slides introduction to the paper "Activation of endogenous human stem cell-associated retroviruses (SCARs) and therapy-resistant phenotypes of malignant tumors"

https://youtu.be/9wiFjng4NgE

http://audioslidesmaker.elsevier.com/Preview/Default.aspx?doi=10.1016/j.canlet.2016.04.014

 

 

Activation of endogenous human stem cell-associated retroviruses (SCARs) and therapy-resistant phenotypes of malignant tumors

Dear friends and colleagues: I am delighted to be able to let you know that very important article entitled “Activation of endogenous human stem cell-associated retroviruses (SCARs) and therapy-resistant phenotypes of malignant tumors” just has been published online in its final form. Below please find the FREE link access to this article. The FREE link is valid for 50 days only.

http://authors.elsevier.com/a/1SvAo_6wxx8k~f

This is fascinating story to read. It is presenting the multiple lines of experimental and clinical evidence that firmly established the link between the SCARs activation, emergence of cancer stem cells, and development of therapy-resistant sub-types of human malignancies diagnosed in multiple organs. It also outlines new diagnostic and therapeutic strategies that specifically tailored for successful diagnosis, targeting, and eventual eradication of this lethal form of malignant disease. At least some of these therapies may be immediately available and as pointed out in the paper “…may be considered for cancer patients with advanced metastatic disease who do not have other viable options in their fight against these devastating maladies.”

Enjoy the reading and studying this work. The path to victory in our war against cancer is clear. I sincerely hope that you will join us in our life-long fight against terrible diseases that devastated so many families and killed so many of our friends. I would like to encourage you to help us in any way you can to dramatically change the way we think about how cancer develops and how to successfully diagnose, prevent, and treat metastatic disease.

 

TARGETED COMBINATION THERAPY DIRECTED AGAINST MULTIPLE STEMNESS PATHWAY’S GENETIC TARGETS IN CANCER STEM CELLS

TARGETED COMBINATION THERAPY DIRECTED AGAINST MULTIPLE STEMNESS PATHWAY’S GENETIC TARGETS IN CANCER STEM CELLS

Targeted combination therapy directed at multiple genetic targets within stemness pathways in cancer stem cells is one of the most promising new approaches for development of new and efficient treatment of therapy-resistant, clinically-lethal metastatic cancers. How to deliver simultaneously the multiple targeted therapeutics having markedly distinct chemical properties and different pharmacokinetics, bioavailability, stability, and toxicity profiles? How to accomplish this coordinated delivery in vivo with clinically-sufficient precision to avoid toxicity and facilitate on-demand release in selectively targeted cancer cells? The proof of principle experiments are underway to demonstrate the feasibility of our approach to the solution of this critically important problem. Essentially all design, engineering, and lab-scale manufacturing components are in place and now it is time to put them all together into a single therapeutics assembly pipeline. Please stay tuned for follow-up updates and additional information which will be coming soon in the New Projects and Therapeutics sections of our website: http://www.genlighttechnology.com

ENROLLMENT TO GENLIGHT LIFETIME DISCOUNTS MEMBERSHIP PROGRAM IS NOW OPEN

ENROLLMENT TO GENLIGHT LIFETIME DISCOUNTS MEMBERSHIP PROGRAM IS NOW OPEN

We are implementing the pilot program designed to make our services and products more affordable to our clients and customers. Please continue to visit our page soon to learn more.

We will start the program offering the lifetime discounts on all our services and products.

In 2014, these offers will be available exclusively to the individuals who are registered on our Facebook page.

Lifetime discounts will be available through Membership Services.

The become a Member, you must be at least 18 years old, registered at our Facebook page by clicking “Like”, and complete the following two steps:

  1. Choose one of the Membership Services’ Categories

  2. Pay the required Membership Fee

Once you become a Member, your membership fee will NEVER increase. It will remain the same as long as you are alive.

In practical terms it means that one can lock-in and protect the lifetime discount values against inflation. To maintain your eligibility, the membership fee is due on the each anniversary date of your initial enrollment. If you did not use any of our services or did not purchase any of our products during the calendar year, your membership fee will be automatically transferred for the next calendar year.

Please read related Posts on our Facebook page for additional information

www.facebook.com/genlighttech  

Patient-derived orthotopic xenograft (PDOX) models of human cancers

Establishing and preclinical validation of patient-derived orthotopic xenograft (PDOX) models of human cancers faithfully recapitulating biological, genetic, and molecular features of disease in individual cancer patients is a cornerstone of personalized, target-tailored cancer therapies, long-term disease management, early diagnosis of disease recurrence, and identification of novel targeted therapeutic modalities for therapy-resistant types of cancers. A multidisciplinary team of scientists from the Stanford University School of Medicine and other collaborating institutions published a research paper reporting the significant advance in this filed for therapy-resistant form of breast cancer. Genlight Co-founder and CSO, Dr. Gennadi V. Glinsky, MD, Ph.D., is one of the key members of the scientific team implementing this project.

The paper can be found through the search of PubMed and Google Scholar databases.

Zhang et al. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition. Breast Cancer Res. 2014 Apr 7;16(2):R36. PMID: 24708766

http://www.ncbi.nlm.nih.gov/pubmed/24708766

http://breast-cancer-research.com/content/pdf/bcr3640.pdf

 

Genlight Technologies services and products are designed to deliver the advantages of these scientific and technological breakthroughs to cancer patients in the United States and around the world.

GenLight Technologies Personalized Genomics Medicine

http://genlighttechnology.com

www.facebook.com/genlighttech

Translational Oncogenomics Services

In recent years three important developments in translational oncogenomics offer an exceptional promise of progress in our fight against cancer:

  1. Genomic pathways and associated molecular targets activated in therapy-resistant sub-types of human tumors have been identified

  2. Several novel molecular therapeutics designed to target these pathways are being investigated in clinical trials

  3. Patient-derived orthotopic xenograft (PDOX) models faithfully recapitulating biological, genetic, and molecular features of human disease in individual cancer patients have been validated in multiple independent studies

Genlight Technologies services and products are designed to deliver the advantages of these scientific and technological breakthroughs to cancer patients in the United States and around the world.

http://genlighttechnology.com

www.facebook.com/genlighttech

In 2014-2015 we are planning to offer the web-based access to our products and services to customers around the world. Stay in touch to learn more about this exciting new development that should enable the access to state-of-the-art advances in biomedical sciences of health management and disease prevention to many people.